Cyclopharm Limited (ASX:CYC)
Australia · Delayed Price · Currency is AUD 0.9900
+0.0100 (1.02%)
Aug 8, 2025, 4:10 PM AEST
MorphoSys AG Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 27.57 | 26.34 | 22.88 | 17.7 | 14.68 | Upgrade |
Other Revenue | - | - | 1.98 | 2.29 | 3 | Upgrade |
Revenue | 27.57 | 26.34 | 24.85 | 20 | 17.68 | Upgrade |
Revenue Growth (YoY) | 4.68% | 5.97% | 24.30% | 13.09% | 3.93% | Upgrade |
Cost of Revenue | 9.64 | 10.26 | 7.44 | 5.04 | 3.96 | Upgrade |
Gross Profit | 17.93 | 16.08 | 17.41 | 14.95 | 13.72 | Upgrade |
Selling, General & Admin | 30.62 | 21.48 | 18.69 | 16.68 | 14.35 | Upgrade |
Research & Development | 0.37 | 3.69 | 3.44 | 1.66 | 3.54 | Upgrade |
Other Operating Expenses | - | - | 0.35 | 0.52 | 0.4 | Upgrade |
Operating Expenses | 32.46 | 26.11 | 23.41 | 19.61 | 19.2 | Upgrade |
Operating Income | -14.52 | -10.02 | -6 | -4.66 | -5.48 | Upgrade |
Interest Expense | -0.28 | -0.19 | -0.27 | -0.09 | -0.21 | Upgrade |
Interest & Investment Income | 0.67 | 0.49 | 0.11 | 0 | 0 | Upgrade |
Earnings From Equity Investments | 0.92 | 0.8 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 0.17 | 0.19 | 0.12 | 0.26 | -0.65 | Upgrade |
Other Non Operating Income (Expenses) | -0.04 | -0.02 | - | - | - | Upgrade |
EBT Excluding Unusual Items | -13.08 | -8.77 | -6.03 | -4.49 | -6.34 | Upgrade |
Gain (Loss) on Sale of Assets | -0 | - | - | - | - | Upgrade |
Asset Writedown | - | 3.16 | - | - | - | Upgrade |
Legal Settlements | - | 1.28 | - | - | 0 | Upgrade |
Other Unusual Items | - | - | - | - | 0.49 | Upgrade |
Pretax Income | -13.07 | -4.19 | -6.03 | -4.35 | -5.84 | Upgrade |
Income Tax Expense | 0.13 | 0.51 | 0.58 | 0.69 | 0.2 | Upgrade |
Net Income | -13.2 | -4.7 | -6.61 | -5.04 | -6.04 | Upgrade |
Net Income to Common | -13.2 | -4.7 | -6.61 | -5.04 | -6.04 | Upgrade |
Shares Outstanding (Basic) | 103 | 93 | 92 | 90 | 77 | Upgrade |
Shares Outstanding (Diluted) | 103 | 93 | 92 | 90 | 77 | Upgrade |
Shares Change (YoY) | 11.05% | 0.53% | 2.77% | 17.10% | 12.43% | Upgrade |
EPS (Basic) | -0.13 | -0.05 | -0.07 | -0.06 | -0.08 | Upgrade |
EPS (Diluted) | -0.13 | -0.05 | -0.07 | -0.06 | -0.08 | Upgrade |
Free Cash Flow | -13.38 | -7.43 | -7.94 | -2.47 | -9.13 | Upgrade |
Free Cash Flow Per Share | -0.13 | -0.08 | -0.09 | -0.03 | -0.12 | Upgrade |
Dividend Per Share | - | 0.005 | 0.010 | 0.010 | 0.010 | Upgrade |
Dividend Growth | - | -50.00% | - | - | - | Upgrade |
Gross Margin | 65.04% | 61.06% | 70.06% | 74.78% | 77.58% | Upgrade |
Operating Margin | -52.68% | -38.06% | -24.13% | -23.31% | -31.01% | Upgrade |
Profit Margin | -47.87% | -17.85% | -26.60% | -25.21% | -34.18% | Upgrade |
Free Cash Flow Margin | -48.52% | -28.23% | -31.94% | -12.36% | -51.63% | Upgrade |
EBITDA | -13.69 | -9.36 | -5.36 | -4.19 | -4.86 | Upgrade |
EBITDA Margin | -49.65% | -35.55% | -21.55% | -20.96% | -27.50% | Upgrade |
D&A For EBITDA | 0.83 | 0.66 | 0.64 | 0.47 | 0.62 | Upgrade |
EBIT | -14.52 | -10.02 | -6 | -4.66 | -5.48 | Upgrade |
EBIT Margin | -52.68% | -38.06% | -24.13% | -23.31% | -31.01% | Upgrade |
Revenue as Reported | 27.57 | 26.34 | 24.96 | 20.14 | 17.69 | Upgrade |
Advertising Expenses | 1.47 | 0.98 | 0.54 | 0.3 | 0.21 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.